Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines.  

Distinctive Features: Funding from this award mechanism must support a clinical trial.

·        Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.

·        Preliminary data are required.

·        The inclusion of community-based participatory research (CBPR) approaches is required.

·        The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.

○       Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.

○       Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.

·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.